Biotech Acquisition Company Class A Ordinary Shares
BIOT
BIOT was delisted on the 2nd of February, 2023.
68 hedge funds and large institutions have $226M invested in Biotech Acquisition Company Class A Ordinary Shares in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 6 closing their positions.
0% more capital invested
Capital invested by funds: $226M → $226M (+$279K)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less funds holding
Funds holding: 69 → 68 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$3.75M |
| 2 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
+$1.99M |
| 3 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
+$1.15M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$793K |
| 5 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
+$557K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Cohanzick Management
Pleasantville,
New York
|
-$7.93M |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$2.02M |
| 3 |
MSU
Mizuho Securities USA
New York
|
-$1.95M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.44M |
| 5 |
JP Morgan Chase
New York
|
-$995K |
BIOT Hedge Fund Activity: Q4 2022 in Review
68 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q4 2022, worth a combined $226M — up 0.12% from $226M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BIOT and 5 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 8 added.
The largest buyer was Aristeia Capital, adding an estimated $3.75M. The largest seller was Cohanzick Management, exiting entirely with an estimated $7.93M sold.
- 68 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q4 2022, down from 69 in Q3 2022.
- Funds reported $226M of Biotech Acquisition Company Class A Ordinary Shares stock for Q4 2022, up 0.12% quarter-over-quarter.
- 5 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q4 2022 and 6 closed out, a net change of -1 holder.
- The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q4 2022 was Aristeia Capital, an estimated $3.75M added.
- The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q4 2022 was Cohanzick Management, an estimated $7.93M sold.
Based on aggregated 13F filings for Q4 2022.